PGT Innovations Inc (NYSE:PGTI) Receives Consensus Rating of “Buy” from Analysts

Share on StockTwits

Shares of PGT Innovations Inc (NYSE:PGTI) have been assigned an average rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $22.00.

A number of research analysts recently issued reports on PGTI shares. ValuEngine lowered PGT Innovations from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Zacks Investment Research raised PGT Innovations from a “strong sell” rating to a “hold” rating in a report on Thursday, January 9th.

NYSE:PGTI opened at $16.89 on Friday. The business’s 50-day moving average price is $15.56 and its 200 day moving average price is $15.68. The firm has a market cap of $967.18 million, a P/E ratio of 19.41, a PEG ratio of 1.19 and a beta of 0.85. PGT Innovations has a 52-week low of $13.30 and a 52-week high of $18.48. The company has a quick ratio of 2.83, a current ratio of 3.56 and a debt-to-equity ratio of 0.92.

In related news, Director Rodney Hershberger sold 10,151 shares of PGT Innovations stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $15.96, for a total transaction of $162,009.96. Following the transaction, the director now directly owns 1,366,345 shares of the company’s stock, valued at $21,806,866.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 33,939 shares of company stock worth $512,263. 5.80% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. increased its position in PGT Innovations by 1.1% in the 4th quarter. UBS Asset Management Americas Inc. now owns 62,682 shares of the construction company’s stock worth $935,000 after buying an additional 688 shares during the period. Bank of New York Mellon Corp increased its position in PGT Innovations by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 758,984 shares of the construction company’s stock worth $11,316,000 after buying an additional 2,989 shares during the period. Goldman Sachs Group Inc. increased its position in PGT Innovations by 30.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 108,121 shares of the construction company’s stock worth $1,612,000 after buying an additional 25,031 shares during the period. Guggenheim Capital LLC increased its position in PGT Innovations by 1.3% in the 4th quarter. Guggenheim Capital LLC now owns 392,247 shares of the construction company’s stock worth $5,848,000 after buying an additional 4,871 shares during the period. Finally, UBS Group AG increased its position in PGT Innovations by 35.3% in the 4th quarter. UBS Group AG now owns 79,596 shares of the construction company’s stock worth $1,186,000 after buying an additional 20,769 shares during the period. Institutional investors and hedge funds own 92.27% of the company’s stock.

PGT Innovations Company Profile

PGT Innovations, Inc manufactures and supplies impact-resistant residential windows and doors in the Southeastern United States, Western United States, the Gulf Coast, Coastal mid-Atlantic, the Caribbean, Central America, and Canada. It offers heavy-duty aluminum or vinyl frames with laminated glass to provide protection from hurricane-force winds and wind-borne debris; and non-impact vinyl windows with insulating glass and multi-chambered frames for various climate zones.

See Also: Cost of Debt

Analyst Recommendations for PGT Innovations (NYSE:PGTI)

Receive News & Ratings for PGT Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PGT Innovations and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.